Cambridge, UK – A groundbreaking new treatment approach developed by Cambridge researchers has achieved an unprecedented 100% survival rate over three years for patients battling aggressive, inherited breast cancers. This significant discovery, which challenges conventional treatment protocols, could redefine the standard of care for individuals with early-stage breast cancer carrying BRCA1 and BRCA2 gene mutations.
The innovative strategy, trialled under the "Partner" study, combines chemotherapy with a targeted cancer drug, olaparib, administered before surgery. Crucially, the trial introduced a carefully timed 48-hour gap between the two treatments, a seemingly minor adjustment that appears to unlock profound benefits. Published today in the prestigious journal Nature Communications, these findings represent a beacon of hope for a patient population facing particularly challenging prognoses.
Unprecedented Success: The Main Facts
The core of this monumental achievement lies in the Partner trial’s ability to achieve a 100% survival rate three years post-surgery for all 39 patients who received the novel pre-surgical treatment regimen. This stands in stark contrast to the control arm of the study, where patients received chemotherapy alone and recorded an 88% survival rate, with nine relapses and six deaths among 45 participants. The first three years following surgery are considered the most critical period, marked by the highest risk of cancer recurrence or fatality. To achieve perfect survival within this window is, as lead researcher Professor Jean Abraham notes, "rare… and incredibly exciting."
Inherited breast cancers, particularly those linked to faulty BRCA1 and BRCA2 genes, are notoriously aggressive and difficult to treat. These genetic mutations gained widespread public awareness in 2013 when actress Angelina Jolie, a BRCA1 carrier, underwent a preventative double mastectomy. While preventative measures exist, effective treatment for diagnosed cases remains a critical area of research.
The Partner trial’s success is attributed to two key innovations: the strategic integration of olaparib pre-surgery, and the precise timing of its administration relative to chemotherapy. Olaparib, a targeted cancer drug known as a PARP inhibitor, is already approved for use on the NHS, typically administered post-surgery for 12 months. However, the Partner trial demonstrates its efficacy and potential cost-saving benefits when used pre-surgery for a shorter duration of 12 weeks.
A New Chronology of Care: The Partner Trial’s Journey
The journey to this pivotal discovery began with a deep understanding of the biological intricacies of BRCA-mutated cancers and the existing limitations of standard treatment. For patients diagnosed with early-stage breast cancer linked to BRCA1 and BRCA2 gene mutations, the standard approach involves neoadjuvant therapy – chemotherapy and sometimes immunotherapy – aimed at shrinking the tumour before surgical removal. Despite these efforts, the aggressive nature of these cancers means that a significant number of patients still face relapse within the crucial three-year post-operative period.
The Genesis of an Idea
The idea for the Partner trial emerged from a "chance conversation," as Professor Jean Abraham, a consultant at Addenbrooke’s Hospital and Professor of Precision Breast Cancer Medicine at the University of Cambridge, recounts. This serendipitous discussion with Mark O’Connor, Chief Scientist in Early Oncology R&D at nearby AstraZeneca, sparked the concept of optimizing the delivery of existing treatments. The central hypothesis revolved around leveraging the distinct mechanisms of chemotherapy and PARP inhibitors, and exploring whether their sequential administration, with a specific interval, could enhance their combined effectiveness while minimizing patient toxicity.
Designing the Innovative Regimen
The Partner trial, led by Addenbrooke’s Hospital, part of Cambridge University Hospitals (CUH) NHS Foundation Trust, and the University of Cambridge, was meticulously designed. It recruited patients from 23 NHS sites across the UK, creating a robust, multi-centre study. The experimental arm of the trial introduced olaparib, taken orally as tablets, into the pre-surgical treatment landscape.
The critical innovation, however, was the precise timing. Researchers hypothesised that a brief interval between chemotherapy and olaparib could be beneficial. Chemotherapy broadly targets rapidly dividing cells, including cancer cells and healthy cells like those in bone marrow. Olaparib, as a PARP inhibitor, exploits a specific vulnerability in BRCA-deficient cancer cells – a concept known as synthetic lethality. By leaving a 48-hour "gap" between the two drugs, the researchers aimed to allow a patient’s healthy bone marrow cells to begin recovering from the non-specific assault of chemotherapy, while leaving the DNA-damaged tumour cells susceptible to the targeted attack of olaparib. This strategic pause was central to the trial’s design and ultimately, its success.
From Diagnosis to Recovery: Jackie’s Story
For patients like Jackie Van Bochoven, 59, from South Cambridgeshire, the trial offered a lifeline. Diagnosed in February 2019 with a small but aggressive tumour, Jackie’s initial reaction was one of profound shock and worry, especially given her family history of breast cancer. "When I had the diagnosis, I was completely shocked and numb, I thought about my children, and my mum and sister who were diagnosed with breast cancer. I was pretty worried," she recalls.
Jackie became one of the 39 patients to receive the novel treatment protocol. Six years on, she stands as a testament to the trial’s success. "Six years on, I’m well and cancer free. I’m back at work, enjoying life and spending time with my family. When you’ve had cancer, I think you look at life differently and every day is a bonus," she shares, her words underscoring the profound impact of effective treatment on a patient’s life and perspective. Her experience, mirrored by all other participants in the intervention arm, provides compelling human evidence of the trial’s clinical efficacy.
Robust Data and Biological Rationale: Supporting the Findings
The statistical data from the Partner trial is striking and provides a strong foundation for the potential adoption of this new approach.
The Power of 100%
Out of the 39 patients who received chemotherapy followed by the carefully timed olaparib regimen, only one patient experienced a relapse three years after surgery, and critically, 100% of these patients survived. This figure is almost unheard of in trials for aggressive cancers, especially within such a critical post-operative period.
In contrast, the control arm, comprising 45 patients who received chemotherapy only, showed an 88% survival rate three years post-surgery. Within this group, nine patients relapsed, and tragically, six of those nine patients died. The stark difference between the two arms – 100% survival versus 88% with significant mortality – highlights the dramatic improvement offered by the Partner approach.
The Science Behind the Gap
The biological explanation for the success of the 48-hour gap is rooted in the distinct mechanisms of action of chemotherapy and PARP inhibitors.
- Chemotherapy’s Broad Impact: Conventional chemotherapy agents, such as platinum-based drugs often used for BRCA-mutated cancers, inflict widespread DNA damage and disrupt cell division. While highly effective against rapidly proliferating cancer cells, they also affect healthy cells, particularly those with high turnover rates like bone marrow stem cells, leading to side effects such as myelosuppression (reduced blood cell production).
- Olaparib and Synthetic Lethality: Olaparib is a PARP inhibitor. PARP (Poly ADP-ribose polymerase) proteins are crucial for repairing single-strand DNA breaks. In cells with functional BRCA1 or BRCA2 genes, if PARP is inhibited, the cell can still rely on the BRCA pathway to repair DNA damage. However, in cancer cells that already have faulty BRCA genes, the inhibition of PARP becomes lethal. This is because these cells are highly dependent on PARP for DNA repair; block PARP, and with a non-functional BRCA pathway, the cell accumulates irreparable DNA damage and dies. This concept is known as "synthetic lethality."
- Optimizing the Sequence: The 48-hour gap appears to be the sweet spot. It provides sufficient time for healthy bone marrow cells, which have intact BRCA pathways, to recover from the initial assault of chemotherapy. This recovery minimizes the overall toxicity to the patient. Simultaneously, the cancer cells, already compromised by chemotherapy-induced DNA damage and lacking functional BRCA repair, remain highly vulnerable. When olaparib is introduced after this brief recovery period, it delivers a devastating blow to the already weakened cancer cells, exploiting their unique genetic Achilles’ heel without causing undue harm to the recovering healthy tissues. This careful timing ensures maximum therapeutic effect with potentially reduced side effects.
This nuanced understanding of cellular repair mechanisms and drug interactions underscores the scientific elegance of the Partner trial’s design and its remarkable outcomes.
Official Responses and Broader Implications
The findings of the Partner trial have elicited widespread enthusiasm from leading experts and organizations within the cancer research community, recognizing its potential to usher in a new era of personalized cancer medicine.
Voices of Hope and Caution
Professor Jean Abraham, whose leadership was instrumental in the trial, expressed profound excitement: "It is rare to have a 100% survival rate in a study like this and for these aggressive types of cancer. We’re incredibly excited about the potential of this new approach, as it’s crucial that we find a way to treat and hopefully cure patients who are diagnosed with BRCA1 and BRCA2 related cancers." Her optimism is tempered with the professional understanding that further validation is necessary, but the initial results are undeniably compelling.
Mark O’Connor of AstraZeneca, a key industry partner, highlighted the collaborative spirit and scientific insight that drove the trial: "The Partner trial highlights the importance of detecting and treating cancer early, and the value of innovative science in informing clinical trial design, in this case using bone marrow stem cells to identify the combination gap schedule. While the findings need to be validated in a larger study, they’re incredibly exciting, and have the potential to transform outcomes for patient populations who have unmet clinical need." His comments underscore the crucial role of basic science in translating into clinical breakthroughs.
Michelle Mitchell, Chief Executive of Cancer Research UK, which funded the trial, emphasized the broader strategic importance of the findings: "One of the best ways that we can beat cancer sooner is by making more effective use of treatments that are already available to us." She added, "While this research is still in its infancy, it is an exciting discovery that adding olaparib at a carefully-timed stage of treatment can potentially give patients with this specific type of breast cancer more time with their loved ones. Research like this can help find safer and kinder ways to treat certain types of cancer. Further studies in more patients are needed to confirm whether this new technique is safe and effective enough to be used by the NHS." Her statement perfectly encapsulates the dual promise of the trial: immediate hope for patients and a blueprint for future research.
Beyond Breast Cancer: A Wider Horizon
The implications of the Partner trial extend far beyond breast cancer. The findings have the potential to be applied to other cancers caused by faulty copies of BRCA genes. This includes certain types of ovarian, prostate, and pancreatic cancers, which also rely on the BRCA pathway for DNA repair and could therefore be susceptible to a similar treatment strategy. This opens the door to a paradigm shift in how these genetically predisposed cancers are approached, potentially offering new hope across multiple cancer types.
Economic and Quality of Life Benefits for the NHS
Beyond the undeniable clinical benefits, the Partner approach also holds significant promise for the National Health Service (NHS) in terms of cost-effectiveness and patient quality of life. Currently, patients offered olaparib typically take the drug post-surgery for 12 months. In contrast, patients on the Partner trial took the tablets pre-surgery for a much shorter duration of 12 weeks. This reduction in treatment duration could lead to substantial cost savings for the NHS by decreasing drug expenditure over time.
Furthermore, a shorter course of treatment, especially one delivered pre-surgically, could mean a less toxic and more manageable experience for patients. Reducing the overall treatment burden can improve patients’ quality of life during and after therapy, allowing them to recover faster and return to normal life sooner, as exemplified by Jackie Van Bochoven’s experience. This potential for a "kinder" treatment regimen is a crucial consideration for healthcare providers and patients alike.
The Cambridge Ecosystem: A Model of Collaboration
The success of the Partner trial is also a powerful testament to the collaborative ecosystem thriving on the Cambridge Biomedical Campus. This type of multi-faceted collaboration between NHS clinical expertise, world-class academic research from the University of Cambridge, and innovative industry partners like AstraZeneca, reflects a shared vision for advancing cancer care.
This collaborative model is the driving force behind the planned Cambridge Cancer Research Hospital, a specialist facility set to be built on Europe’s leading life sciences campus. This new hospital aims to bring together clinical experts from Addenbrooke’s Hospital with scientists from the University of Cambridge, the Cancer Research UK Cambridge Centre, and industry partners under one roof. The goal is to accelerate the creation of new diagnostics and treatments, detect the earliest signs of cancer, and deliver truly personalized, precision medicine tailored to individual patient needs. The Partner trial serves as a compelling proof-of-concept for this ambitious vision.
The Road Ahead: Validating and Expanding the Discovery
While the initial results are incredibly promising, Professor Abraham and her team are acutely aware that further rigorous research is essential before this approach can be widely adopted. The next phase of the research is already being planned, with a clear focus on replicating the results in a larger, multicentre study.
This larger study will aim to:
- Validate Efficacy: Confirm the 100% survival rate and the significant reduction in relapse rates in a broader and more diverse patient population. This is crucial for establishing the statistical robustness and generalizability of the findings.
- Confirm Toxicity Profile: Further investigate and confirm that the Partner approach indeed offers a less toxic treatment regimen compared to the current standard of care, ensuring improved patient tolerability and quality of life.
- Assess Cost-Effectiveness: Conduct comprehensive health economic analyses to definitively demonstrate the cost-saving benefits for healthcare systems like the NHS, considering both drug costs and the wider societal costs associated with long-term treatment and relapse management.
- Explore Broader Applicability: Continue research into the potential application of this timed treatment strategy to other BRCA-related cancers, and possibly even other cancer types with similar DNA repair deficiencies.
The Partner trial was a product of extensive collaboration and funding, sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, funded by Cancer Research UK and AstraZeneca, and supported by the NIHR Cambridge Biomedical Research Centre, the Cancer Research UK Cambridge Centre, and Addenbrooke’s Charitable Trust (ACT). This collective effort underscores the significant investment and belief in the potential of this innovative research.
The journey from a "chance conversation" to a 100% survival rate is a testament to the power of dedicated research, strategic collaboration, and a relentless pursuit of better patient outcomes. While the scientific community eagerly awaits the results of larger validation studies, the Partner trial has already etched its mark, offering a tangible glimpse into a future where aggressive inherited cancers may no longer carry such a dire prognosis.
About the Author
